Alnylam's $700M investment from Genzyme brings massive stock gains
January 13, 2014 at 13:34 PM EST
A deal that an executive at Alnylam Pharmaceuticals called “transformational” not only for the company, but the cutting-edge technology known as RNA interference, boosted the company’s stock price more than 50 percent this morning to a new all-time high...
